Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Coca-Cola Femsa
KOF
$23B
| $76.5M | 0.1% |
903,500
-17,600
| -2% | -$1.37M |
|
|
TSS
252
DELISTED
Total System Services, Inc.
TSS
| $76M | 0.1% |
1,303,965
+598,500
| +85% | +$34.2M |
|
253
Manhattan Associates
MANH
$11.4B
| $75.9M | 0.1% |
1,578,360
-155,400
| -9% | -$7.36M |
|
254
Dolby
DLB
$5.75B
| $75.8M | 0.1% |
1,549,100
+191,600
| +14% | +$9.77M |
|
255
SLB Ltd
SLB
$79.7B
| $75.2M | 0.1% |
+1,142,404
| New | +$81.9M |
|
|
EQC
256
DELISTED
Equity Commonwealth
EQC
| $75.1M | 0.1% |
2,376,675
+490,700
| +26% | +$15.5M |
|
257
Hanover Insurance
THG
$7.73B
| $74.7M | 0.1% |
842,900
+254,000
| +43% | +$21.8M |
|
258
Dick's Sporting Goods
DKS
$18.4B
| $74.6M | 0.1% |
1,874,100
-180,500
| -9% | -$8.14M |
|
259
Royal Bank of Canada
RY
$292B
| $74.3M | 0.09% |
1,023,777
-45,200
| -4% | -$3.17M |
|
260
Enterprise Products Partners
EPD
$81.8B
| $74.2M | 0.09% |
2,739,749
+1,360,627
| +99% | +$36.9M |
|
261
EOG Resources
EOG
$75.2B
| $74M | 0.09% |
817,600
+43,600
| +6% | +$4.02M |
|
262
Bath & Body Works
BBWI
$3.81B
| $72.6M | 0.09% |
1,666,527
-992,445
| -37% | -$40.7M |
|
|
PCH
263
DELISTED
PotlatchDeltic
PCH
| $72.6M | 0.09% |
1,588,200
+59,647
| +4% | +$2.74M |
|
264
Adeia
ADEA
$3.06B
| $72.5M | 0.09% |
9,201,329
-54,810
| -0.6% | -$463K |
|
265
Xerox
XRX
$423M
| $72M | 0.09% |
2,507,766
-418,306
| -14% | -$11.8M |
|
266
Microchip Technology
MCHP
$44B
| $71.9M | 0.09% |
+1,862,056
| New | +$73.2M |
|
267
Telephone and Data Systems
TDS
$3.84B
| $71.8M | 0.09% |
2,587,808
+500
| +0% | +$13.7K |
|
268
CMS Energy
CMS
$21.8B
| $71.2M | 0.09% |
1,540,000
+661,300
| +75% | +$30.6M |
|
269
Centene
CNC
$32.1B
| $70.8M | 0.09% |
1,772,632
+147,400
| +9% | +$5.56M |
|
270
Telkom Indonesia
TLK
$14.4B
| $70.6M | 0.09% |
2,095,600
+323,000
| +18% | +$10.5M |
|
|
271
Meta Platforms (Facebook)
META
$1.53T
| $70.4M | 0.09% |
466,500
-1,735,300
| -79% | -$258M |
|
|
DD
272
DELISTED
Du Pont De Nemours E I
DD
| $70M | 0.09% |
867,900
+419,000
| +93% | +$33.5M |
|
273
CorVel
CRVL
$3.09B
| $69.9M | 0.09% |
4,422,000
+29,541
| +0.7% | +$447K |
|
274
Viavi Solutions
VIAV
$9.47B
| $69.8M | 0.09% |
6,628,606
+1,756,862
| +36% | +$18.9M |
|
275
Grand Canyon Education
LOPE
$3.76B
| $69.8M | 0.09% |
890,100
+70,500
| +9% | +$5.4M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.